AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 95 filers reported holding AKERO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $150,678 | +31.5% | 2,979 | +21.4% | 0.01% | +33.3% |
| Q2 2023 | $114,577 | +51.2% | 2,454 | +23.9% | 0.01% | +50.0% |
| Q1 2023 | $75,793 | -35.8% | 1,981 | -8.1% | 0.00% | -20.0% |
| Q4 2022 | $118,149 | +95.4% | 2,156 | +21.4% | 0.01% | +66.7% |
| Q3 2022 | $60,473 | +260.3% | 1,776 | 0.0% | 0.00% | +200.0% |
| Q2 2022 | $16,783 | -33.4% | 1,776 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $25,201 | -84.2% | 1,776 | -76.4% | 0.00% | -50.0% |
| Q4 2021 | $159,175 | -5.4% | 7,526 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $168,206 | -9.9% | 7,526 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $186,720 | +66.7% | 7,526 | +95.0% | 0.00% | +50.0% |
| Q1 2021 | $111,979 | +12.4% | 3,860 | 0.0% | 0.00% | +100.0% |
| Q4 2020 | $99,588 | -16.2% | 3,860 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $118,849 | +23.6% | 3,860 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $96,191 | – | 3,860 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |